Cargando…

特发性肺纤维化合并肺癌发病机制的研究进展

Idiopathic pulmonary fibrosis (IPF) is characterized by diffuse alveolitis and disorder of alveolar structure and eventually leads to pulmonary interstitial fibrosis. The cause of IPF is unknown and there is no effective treatment for IPF. There is no effective treatment for IPF, mainly to delay dis...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467990/
https://www.ncbi.nlm.nih.gov/pubmed/32838491
http://dx.doi.org/10.3779/j.issn.1009-3419.2020.102.23
_version_ 1783578129556570112
collection PubMed
description Idiopathic pulmonary fibrosis (IPF) is characterized by diffuse alveolitis and disorder of alveolar structure and eventually leads to pulmonary interstitial fibrosis. The cause of IPF is unknown and there is no effective treatment for IPF. There is no effective treatment for IPF, mainly to delay disease progression and improve patient's quality of life. At present, the incidence of IPF with lung cancer (IPF-LC) has increased significantly, which resulted in higher mortality and reduced quality of life. IPF-LC is more common in men, elderly, and smokers. It is a fatal disease and its clinical manifestations lack specificity. IPF-LC has no clear treatment plan, meanwhile, the median survival time is short, and the prognosis is poor. At present, the pathogenesis and treatment plan of IPF-LC are not clear. This article provides a brief review of the current research on the risk factors, pathogenesis, clinical characteristics and treatment of IPF-LC.
format Online
Article
Text
id pubmed-7467990
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-74679902020-09-03 特发性肺纤维化合并肺癌发病机制的研究进展 Zhongguo Fei Ai Za Zhi 综述 Idiopathic pulmonary fibrosis (IPF) is characterized by diffuse alveolitis and disorder of alveolar structure and eventually leads to pulmonary interstitial fibrosis. The cause of IPF is unknown and there is no effective treatment for IPF. There is no effective treatment for IPF, mainly to delay disease progression and improve patient's quality of life. At present, the incidence of IPF with lung cancer (IPF-LC) has increased significantly, which resulted in higher mortality and reduced quality of life. IPF-LC is more common in men, elderly, and smokers. It is a fatal disease and its clinical manifestations lack specificity. IPF-LC has no clear treatment plan, meanwhile, the median survival time is short, and the prognosis is poor. At present, the pathogenesis and treatment plan of IPF-LC are not clear. This article provides a brief review of the current research on the risk factors, pathogenesis, clinical characteristics and treatment of IPF-LC. 中国肺癌杂志编辑部 2020-08-20 /pmc/articles/PMC7467990/ /pubmed/32838491 http://dx.doi.org/10.3779/j.issn.1009-3419.2020.102.23 Text en 版权所有©《中国肺癌杂志》编辑部2020 This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/.
spellingShingle 综述
特发性肺纤维化合并肺癌发病机制的研究进展
title 特发性肺纤维化合并肺癌发病机制的研究进展
title_full 特发性肺纤维化合并肺癌发病机制的研究进展
title_fullStr 特发性肺纤维化合并肺癌发病机制的研究进展
title_full_unstemmed 特发性肺纤维化合并肺癌发病机制的研究进展
title_short 特发性肺纤维化合并肺癌发病机制的研究进展
title_sort 特发性肺纤维化合并肺癌发病机制的研究进展
topic 综述
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467990/
https://www.ncbi.nlm.nih.gov/pubmed/32838491
http://dx.doi.org/10.3779/j.issn.1009-3419.2020.102.23
work_keys_str_mv AT tèfāxìngfèixiānwéihuàhébìngfèiáifābìngjīzhìdeyánjiūjìnzhǎn
AT tèfāxìngfèixiānwéihuàhébìngfèiáifābìngjīzhìdeyánjiūjìnzhǎn